Stockreport

Xeris Presents New Post Hoc Analysis on Effects of Levoketoconazole (Recorlev®) in Cushing's Syndrome Patients at ENDO 2024 [Yahoo! Finance]

Xeris Biopharma Holdings, Inc.  (XERS) 
Last xeris biopharma holdings, inc. earnings: 3/11 06:00 am Check Earnings Report
PDF Lower mUFC at baseline was also associated with lower maintenance dose requirements and lower rates of potentially clinically important liver-related adverse events and [Read more]